Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

PHASE3TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 17, 2008

Primary Completion Date

February 22, 2010

Study Completion Date

February 22, 2010

Conditions
Chronic Pain
Interventions
DRUG

Oxymorphone ER

"Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications"

Trial Locations (13)

17112

Hershey Medical Center, Hershey

20010

Children's National Medical Center, Washington D.C.

27103

The Center for Clinical Research, Winston-Salem

30060

Taylor Research, LLC, Marietta

32257

Florida Institute of Medical Research, Jacksonville

33618

St. Joseph's Children's Hospital of Tampa, Tampa

34104

Tukoi Clinical Research, Miami

40202

University of Louisville Reserach Foundation, Inc., Louisville

46250

Rehabilitation Associates of Indiana, Indianapolis

72202

Arkansas Childrens's Hospital-Division of Pediatric Anestesia and Pain Medicine, Little Rock

80045

The Children's Hospital, Aurora

94305

Stanford University School of Medicine, Stanford

06106

Connecticut Children's Medical Center, Hartford

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY